#Pfizer COVID-19 Treatment Drugs Approved for Import Registration # #辉瑞口服药可降低89% Risk of Hospitalization Death # Pfizer COVID-19 Oral Drugs Have Been Conditionally Approved by the Mainland Food and Drug Administration, which has given the mainland another treatment for the treatment of NEW Crown Pneumonia. According to the treatment effect data released by Pfizer on its new crown oral specific drug, it is shown to reduce the risk of hospital death by 89%.
From the data point of view, Pfizer's new crown oral drug is actually not magical. Although it can reduce the risk of hospital death by 89% is quite eye-catching. However, this data is actually only average on the mainland. Because the treatment effect of the new crown pneumonia in the mainland is obviously better than that of Pfizer's oral drug on the new crown. Because at present, there are almost no deaths of new crown pneumonia patients in the mainland, and the number of deaths is very small. Therefore, Pfizer's new crown oral medicine is not worth showing off in the mainland.
The size of the market for Pfizer's COVID-19 oral drugs in mainland China depends on their price. If the price is low, there may be a certain market, but if the price is high, then its prospects on the mainland are difficult to be optimistic. After all, the current treatment of new crown pneumonia in the mainland is publicly funded treatment, and the cost is borne by the state, so import procurement is also a unified arrangement of the state. If the price is too high, there is obviously no need to purchase. After all, under the condition that the country uniformly bears the cost of treatment, it is not very likely that individuals will purchase oral COVID-19 drugs. Headlines hit list
